A Peninsula drug company that hoped to bring fast relief to migraine sufferers with a nasal spray version of a longtime drug instead blew its second late-stage clinical trial in little more than two years.
The co-primary endpoints of the trial were freedom from pain and"most bothersome symptom," a catch-all category for how persons with migraines designate associated symptoms, including nausea, eye discomfort in bright light, called photophobia, and fear of loud sounds. Injectable DHE has been used to treat migraines for years and two decades ago a liquid spray DHE was approved by the Food and Drug Administration. But that nose delivery has a variable results and requires migraine sufferers to crack a vial of the drug and connect it to a sprayer before shooting it up their nostrils four times.
It's been a costly ride. After Satsuma went public with an $82.5 million IPO in September 2019 — six months before Covid-19 pandemic shutdowns — it had $118.9 million in cash, equivalents and short-term marketable securities. That figure had slipped to an estimated $59.4 million by the end of October.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Most Admired CEOs: John Sensiba of Sensiba San Filippo LLP - San Francisco Business TimesSensiba San Filippo LLP Managing Partner John Sensiba talks growth and becoming a B Corp: 'We went from 190 people at the beginning of the pandemic in our firm to over 350 people today.'
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »
San Francisco's newest condo developments reap diverging fortunes - San Francisco Business TimesWhile some towers are at or near capacity, other developments, especially South of Market, have multiple units unsold. Vancancy tax will help. Lmao.
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »
Most Admired CEOs: Jacqueline Garcel of Latino Community Foundation - San Francisco Business TimesJacqueline Martinez Garcel was born in Washington Heights in Manhattan, but her family moved back to the Dominican Republic when she was young. Her identity was sealed.
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »
Genentech Alzheimer's drug gantenerumab fails 2 late-stage clinical trials - San Francisco Business TimesThe trial failures are the latest disappointments in the Alzheimer's Disease space, especially those promising to have an impact on the memory-robbing disease by removing clumps of the protein beta-amyloid.
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »
State regulations move to change solar power pay structure - San Francisco Business TimesThe California Public Utilities Commission has just thrown a curveball at the solar industry.
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »
Most Admired CEOs: Robert Sanchez of Casa Sanchez Foods - San Francisco Business TimesThe third generation leader of one of the Bay Area's most prominent family businesses dishes on the secrets of lasting success. It's great to hear a positive story about a product I've enjoyed for years.
Fonte: SFBusinessTimes - 🏆 78. / 68 Consulte Mais informação »